EXEL vs. INCY: Exelixis vs. Incyte Stock Comparison
How do Exelixis (EXEL) and Incyte (INCY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Exelixis (EXEL) and Incyte (INCY) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | EXEL | INCY |
|---|---|---|
| Name | Exelixis Inc. | Incyte Corp. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 16.98 billion USD | 24.39 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | April 17, 2000 | November 4, 1993 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | EXEL | INCY |
|---|---|---|
| Total Return (1Y) | 74.98% | 14.06% |
| Total Return (3Y, Annualized) | 50.33% | 32.03% |
| Total Return (5Y, Annualized) | 31.10% | 12.69% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | EXEL | INCY |
|---|---|---|
| Volatility (1Y, Annualized) | 34.17% | 33.19% |
| Beta (5Y) | 0.41 | 0.78 |
| Max Drawdown (5Y) | -35.41% | -40.50% |
| Avg. Volume (3M) | 2.33M | 1.58M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | EXEL | INCY |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 0.29 |
| Sortino Ratio (1Y) | 3.23 | 0.46 |
Profitability
ROE (TTM)
Both Exelixis (EXEL) at 44.32% and Incyte (INCY) at 7.84% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
44.32%
- Max
- 109.18%
- EXEL
- 44.32%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.84%
- Max
- 109.18%
- INCY
- 7.84%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Exelixis (EXEL) at 35.45% keeps the most of each sales dollar — above its industry’s net margin range — and Incyte (INCY) at 6.71% also retains a top-quartile share.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.45%
- EXEL
- 35.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.71%
- Max
- 18.05%
- INCY
- 6.71%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Exelixis (EXEL) at 40.75% and Incyte (INCY) at 33.72% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.75%
- Max
- 83.12%
- EXEL
- 40.75%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.72%
- Max
- 83.12%
- INCY
- 33.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | EXEL | INCY |
|---|---|---|
| ROE (TTM) | 44.32% | 7.84% |
| ROA (TTM) | 23.52% | 17.78% |
| Net Margin (TTM) | 35.45% | 6.71% |
| Operating Margin (TTM) | 40.75% | 33.72% |
| Gross Margin (TTM) | 96.26% | 56.02% |
Growth
Revenue Growth
Both Exelixis (EXEL) at 6.98% and Incyte (INCY) at 21.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than Exelixis (EXEL) at 57.95%, which is closer to a typical peer reading.
Growth Metrics
| Metric | EXEL | INCY |
|---|---|---|
| Revenue Growth (YoY) | 6.98% | 21.22% |
| Revenue Growth (3Y CAGR) | 12.93% | 14.84% |
| EPS Growth (YoY) | 57.95% | 4,173.33% |
| EPS Growth (3Y CAGR) | 70.59% | 61.56% |
Financial Strength
Current Ratio (MRQ)
Both Exelixis (EXEL) at 3.21 and Incyte (INCY) at 3.84 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.21
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- EXEL
- 3.21
- Q1
- 2.47
- Min
- 0.10
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.84
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INCY
- 3.84
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while Exelixis (EXEL) at 0.09 runs a more typical debt-to-equity mix.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.09
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- EXEL
- 0.09
- Q1
- 0.02
- Min
- 0.00
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- INCY
- 0.01
- Min
- 0.00
Financial Strength Metrics
| Metric | EXEL | INCY |
|---|---|---|
| Current Ratio (MRQ) | 3.21 | 3.84 |
| Debt / Equity (MRQ) | 0.09 | 0.01 |
| Net Debt / EBITDA | -0.71 | -1.88 |
Dividends
Dividend Yield (TTM)
Neither Exelixis (EXEL) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- EXEL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Exelixis (EXEL) nor Incyte (INCY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- EXEL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | EXEL | INCY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Exelixis (EXEL) at 20.83 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.83
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- EXEL
- 20.83
- Q1
- 13.30
- Min
- 0.07
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.05
- Max
- 85.34
- INCY
- 61.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Exelixis (EXEL) at 6.80 and Incyte (INCY) at 4.06 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.80
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- EXEL
- 6.80
- Q1
- 3.01
- Min
- 0.01
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.06
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- INCY
- 4.06
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Incyte (INCY) at 4.33 is valued about in line with its industry on P/B ratio, while Exelixis (EXEL) at 9.28 carries an above-peer premium to book — EXEL is pricier on assets.
EXEL
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.28
- Max
- 13.53
- EXEL
- 9.28
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.33
- Max
- 13.53
- Q3
- 6.54
- INCY
- 4.33
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | EXEL | INCY |
|---|---|---|
| P/E Ratio (TTM) | 20.83 | 61.05 |
| P/S Ratio (TTM) | 6.80 | 4.06 |
| P/B Ratio (MRQ) | 9.28 | 4.33 |
| Free Cash Flow Yield (TTM) | 4.47% | 5.28% |